Integrase inhibitor (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Integrase inhibitor" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

1archive-it.org

910^th place

593^rd place

447^th place

338^th place

1semanticscholar.org

11^th place

8^th place

1web.archive.org

1^st place

1^st place

1businesswire.com

615^th place

407^th place

archive-it.org

wayback.archive-it.org

"FDA approval of Isentress (raltegravir)". U.S. Food and Drug Administration. October 12, 2007. Archived from the original on January 12, 2017. Retrieved October 8, 2019.

businesswire.com

"U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection" (Press release). Gilead. February 7, 2018.

doi.org

Steigbigel RT, Cooper DA, Kumar PN, et al. (July 2008). "Raltegravir with optimized background therapy for resistant HIV-1 infection". N. Engl. J. Med. 359 (4): 339–54. doi:10.1056/NEJMoa0708975. PMID 18650512. S2CID 17257548.
USA (2014). "Antiretroviral Therapy: Current Drugs". Infectious Disease Clinics of North America. 28 (3). Ncbi.nlm.nih.gov: 371–402. doi:10.1016/j.idc.2014.06.001. PMC 4143801. PMID 25151562.

fda.gov

"FDA approval of Isentress (raltegravir)". U.S. Food and Drug Administration. October 12, 2007. Archived from the original on January 12, 2017. Retrieved October 8, 2019.

nih.gov

pubmed.ncbi.nlm.nih.gov

Steigbigel RT, Cooper DA, Kumar PN, et al. (July 2008). "Raltegravir with optimized background therapy for resistant HIV-1 infection". N. Engl. J. Med. 359 (4): 339–54. doi:10.1056/NEJMoa0708975. PMID 18650512. S2CID 17257548.
USA (2014). "Antiretroviral Therapy: Current Drugs". Infectious Disease Clinics of North America. 28 (3). Ncbi.nlm.nih.gov: 371–402. doi:10.1016/j.idc.2014.06.001. PMC 4143801. PMID 25151562.

ncbi.nlm.nih.gov

USA (2014). "Antiretroviral Therapy: Current Drugs". Infectious Disease Clinics of North America. 28 (3). Ncbi.nlm.nih.gov: 371–402. doi:10.1016/j.idc.2014.06.001. PMC 4143801. PMID 25151562.

aidsinfo.nih.gov

"Elvitegravir". AIDSinfo. National Institutes of Health. Archived from the original on 2011-09-27. Retrieved 2007-10-13.

semanticscholar.org

api.semanticscholar.org

Steigbigel RT, Cooper DA, Kumar PN, et al. (July 2008). "Raltegravir with optimized background therapy for resistant HIV-1 infection". N. Engl. J. Med. 359 (4): 339–54. doi:10.1056/NEJMoa0708975. PMID 18650512. S2CID 17257548.

web.archive.org

"Elvitegravir". AIDSinfo. National Institutes of Health. Archived from the original on 2011-09-27. Retrieved 2007-10-13.